GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » Cyclically Adjusted PB Ratio

Galectin Therapeutics (FRA:PHPN) Cyclically Adjusted PB Ratio : 10.83 (As of May. 16, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-16), Galectin Therapeutics's current share price is €2.60. Galectin Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €0.24. Galectin Therapeutics's Cyclically Adjusted PB Ratio for today is 10.83.

The historical rank and industry rank for Galectin Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:PHPN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 15.06
Current: 10.94

During the past years, Galectin Therapeutics's highest Cyclically Adjusted PB Ratio was 15.06. The lowest was 0.00. And the median was 0.00.

FRA:PHPN's Cyclically Adjusted PB Ratio is ranked worse than
89.78% of 646 companies
in the Biotechnology industry
Industry Median: 1.76 vs FRA:PHPN: 10.94

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Galectin Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was €-0.926. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.24 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galectin Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Galectin Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Cyclically Adjusted PB Ratio Chart

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.47 6.57 5.31 3.23 5.94

Galectin Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 6.17 4.38 6.23 5.94

Competitive Comparison of Galectin Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Galectin Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Cyclically Adjusted PB Ratio falls into.



Galectin Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Galectin Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.60/0.24
=10.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Galectin Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.926/129.4194*129.4194
=-0.926

Current CPI (Dec. 2023) = 129.4194.

Galectin Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.914 99.695 1.187
201406 0.840 100.560 1.081
201409 0.794 100.428 1.023
201412 0.751 99.070 0.981
201503 0.829 99.621 1.077
201506 0.648 100.684 0.833
201509 0.457 100.392 0.589
201512 0.557 99.792 0.722
201603 0.369 100.470 0.475
201606 0.211 101.688 0.269
201609 0.112 101.861 0.142
201612 0.088 101.863 0.112
201703 0.018 102.862 0.023
201706 -0.080 103.349 -0.100
201709 -0.148 104.136 -0.184
201712 -0.183 104.011 -0.228
201803 -0.136 105.290 -0.167
201806 0.017 106.317 0.021
201809 0.000 106.507 0.000
201812 -0.044 105.998 -0.054
201903 0.089 107.251 0.107
201906 0.772 108.070 0.925
201909 0.757 108.329 0.904
201912 0.686 108.420 0.819
202003 0.643 108.902 0.764
202006 0.541 108.767 0.644
202009 0.437 109.815 0.515
202012 0.316 109.897 0.372
202103 0.235 111.754 0.272
202106 0.208 114.631 0.235
202109 0.100 115.734 0.112
202112 0.005 117.630 0.006
202203 -0.129 121.301 -0.138
202206 -0.278 125.017 -0.288
202209 -0.418 125.227 -0.432
202212 -0.547 125.222 -0.565
202303 -0.704 127.348 -0.715
202306 -0.827 128.729 -0.831
202309 -0.805 129.860 -0.802
202312 -0.926 129.419 -0.926

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galectin Therapeutics  (FRA:PHPN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Galectin Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galectin Therapeutics (FRA:PHPN) Business Description

Traded in Other Exchanges
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines